Nicole Barna - 29 Mar 2023 Form 4 Insider Report for Codiak BioSciences, Inc.

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
30 Mar 2023, 17:12:15 UTC
Prior SEC filing
26 Jan 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Yalonda Howze, Attorney-in-Fact for Nicole Barna

Key filing fact

Nicole Barna filed Form 4 for Codiak BioSciences, Inc. on 30 Mar 2023.

Key facts

  • This page summarizes Nicole Barna's Form 4 filing for Codiak BioSciences, Inc..
  • 2 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 30 Mar 2023, 17:12.

Change

  • Previous filing in this sequence was filed on 26 Jan 2023.
  • Current net transaction value: -$1,208.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CDAKQ transaction

Common Stock

Sale

Transaction value
$887
Shares
-5,373
Change %
-44%
Price
$0.1651*
Shares after
6,781
Date
29 Mar 2023
Ownership
Direct
CDAKQ transaction

Common Stock

Sale

Transaction value
$321
Shares
-1,932
Change %
-28%
Price
$0.1660*
Shares after
4,849
Date
29 Mar 2023
Ownership
Direct
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

SEC remarks

Senior Vice President, Human Resources

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .